Could a prostate cancer drug help fight lung cancer?
NCT ID NCT06512207
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding a hormone therapy (leuprorelin) to an immunotherapy (sintilimab) can help older men with advanced lung cancer. The idea is that lowering sex hormones may rejuvenate the immune system, making the immunotherapy more effective. Eighty men aged 60 and older with stage III or IV non-small cell lung cancer will receive both drugs, and researchers will track tumor shrinkage and immune cell changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
leuprorelin acetate (hormone therapy) and sintilimab (immunotherapy)
What this could lead to
If it works, this combination could offer a new treatment option for advanced lung cancer in older men, potentially improving tumor shrinkage and disease control.
What could go wrong
This is an early-stage trial with only 80 participants, all older men, so results may not apply to others. The combination may cause side effects like fatigue, hormone-related issues, or immune reactions, and may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
Contact
Contact Phone: •••-•••-••••